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Abstract
Background: Catalase is preferentially expressed in bronchiolar and alveolar epithelial cells, and acts as an
endogenous antioxidant enzyme in normal lungs. We thus postulated epithelial damage would be associated with
a functional deficiency of catalase during the development of lung fibrosis.
Methods: The present study evaluates the expression of catalase mRNA and protein in human interstitial
pneumonias and in mouse bleomycin-induced lung injury. We examined the degree of bleomycin-induced
inflammation and fibrosis in the mice with lowered catalase activity.
Results: In humans, catalase was decreased at the levels of activity, protein content and mRNA expression in
fibrotic lungs (n = 12) compared to control lungs (n = 10). Immunohistochemistry revealed a decrease in catalase
in bronchiolar epithelium and abnormal re-epithelialization in fibrotic areas. In C57BL/6J mice, catalase activity was
suppressed along with downregulation of catalase mRNA in whole lung homogenates after bleomycin
administration. In acatalasemic mice, neutrophilic inflammation was prolonged until 14 days, and there was a
higher degree of lung fibrosis in association with a higher level of transforming growth factor-b expression and
total collagen content following bleomycin treatment compared to wild-type mice.
Conclusions: Taken together, these findings demonstrate diminished catalase expression and activity in human
pulmonary fibrosis and suggest the protective role of catalase against bleomycin-induced inflammation and
subsequent fibrosis.
Background
Pulmonary fibrosis is a chronic interstitial lung disease
resulting from damage to the lung parenchyma by vary-
ing patterns of inflammation and fibrosis with a high
mortality rate and poor response to available medical
therapy [1]. An imbalance of oxidants and antioxidants
can alter a number of processes thought to contribute
to the pathogenesis of pulmonary fibrosis, such as acti-
vation of redox-sensitive signaling pathways and tran-
scription factors, modification of immune function,
modulation of the protease/antiprotease balance, and
activation of fibroblasts [2-4]. It is well known that
accumulated inflammatory cells such as neutrophils,
which release toxic oxidants, are also capable of indu-
cing oxidant-mediated lung parenchymal cell toxicity in
the process of fibrosis [4].
Catalase, a 240-kD tetrameric heme protein, is one of
the major intracellular antioxidant enzyme responsible
for detoxifying the hydrogen peroxide produced under
physiological conditions to oxygen and water [5]. Exces-
sive hydrogen peroxide is harmful to almost all cell
components, and thus its rapid and efficient removal is
vitally important for aerobic organisms [6]. Further to
this idea, in one study a transgenic mouse overexpres-
sing catalase localized to mitochondria showed an
extended life span due to enhanced protection of mito-
chondria from reactive oxygen species (ROS), in which
catalase overexpression also suppressed age-related
DNA oxidation in skeletal muscle [7]. It has been
known that damage to the mitochondrial membrane by
ROS leads to a loss in membrane potential and pore-
opening, causing swelling, leakage of cytochrome c, and
initiation of apoptosis [8]. Arita et al. recently reported
that targeting of catalase directly to the mitochondria in
lung epithelial cells protected the cells from hydrogen
peroxide-induced apoptosis [9].
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stages of development, is constitutively expressed in air-
way and alveolar epithelial cells and in macrophages
[10-12], and plays an important role in the endogenous
antioxidant defense system. Studies are limited regarding
the role of catalase in pulmonary fibrosis in humans
[3,13], although catalase was found to be decreased in
airway epithelium exposed to 100% O2 [14], in lung can-
cer [15], and in asthma [16]. The regulatory mechanisms
and role of catalase in the development of pulmonary
fibrosis have largely remained to be determined.
We thus hypothesized that (A) catalase is diminished
in human pulmonary fibrosis and in mouse bleomycin-
induced lung injury, (B) a decrease in catalase
particularly occurs in bronchiolar epithelial cells and/or
in various types of abnormal re-epithelialization in fibro-
tic lungs, and finally (C) the deficiency in catalase activ-
ity in the lungs results in predisposing the lung to
worsening lung inflammation and subsequent fibrosis.
In this study, we found catalase has a protective role in
the lung fibrosis.
Materials and methods
Patients and tissue collection
The study population comprised 12 patients with pul-
monary fibrosis. Appling the diagnostic criteria of the
American Thoracic Society/European Respiratory
Society (ATS/ERS) international multidisciplinary con-
sensus classification [1], each diagnosis was based on
the standard clinical criteria and histopathological ana-
lyses of lung tissues obtained by video-assisted thoraco-
scopy-guided lung biopsy or surgical lobectomy as
previously described [17]. All control lung specimens
were obtained from 10 patients who had never smoked
and who underwent lung lobectomy for small peripheral
tumors. Immediately after biopsy or lobar resection, tis-
sues were frozen as soon as possible before RNA and
protein extraction or were fixed in 10% neutral buffered
formalin for immunohistochemistry as previously
described [18]. Written informed consent to participate
in the study was obtained from all patients, and the
Ethics Committee of Hokkaido University School of
Medicine approved the study. Table 1 summarizes the
clinical characteristics of the control subjects and
patients with pulmonary fibrosis. The mean interval
between the onset of symptoms and pathological diag-
nosis was 19.8 months. Neither the patients nor control
subjects had received any drugs which might cause
drug-induced pneumonitis at the time of this study.
Animals and experimental protocols
Male C57BL/6J mice (6-8 weeks old) were purchased
from CLEA Japan (Tokyo, Japan). The mice were
housed in plastic cages under a 12-h light/dark cycle,
fed standard chow, and given free access to food
and water. Male wild-type mice (C3H/AnLCsaCsa) and
male homozygous acatalasemic mutant mice (C3H/
AnLCsbCsb) at the age of 15 weeks were used [19].
After an intraperitoneal injection of ketamine and xyla-
zine for sedation and anesthesia, 0.05 U of bleomycin
(Blenoxane; Nippon Kayaku, Tokyo, Japan) was intratra-
cheally administrated as described [20]. After 7, 14, and
21 days, the animals were killed and their lungs were
processed as described below. Mice that had not under-
gone manipulation served as controls. All experimental
protocols and procedures were approved by the Ethics
Committee on Animal Research of the Hokkaido Uni-
versity School of Medicine.
Bronchoalveolar lavage (BAL) and sampling of mouse
lung tissue
Mice were sacrificed by CO2 narcosis, and then the
lungs were lavaged with 0.6 ml of saline three times
through a tracheal cannula. Total cell counts and cell
differentials in the BAL fluid were determined as
described [20]. After BAL was performed, the lungs
were fixed by inflation with 10% buffered formalin
(Mildform 10N; Wako Pure Chemical Industries, Osaka,
Japan) at a constant pressure of 25 cm H2Oa n d
embedded in paraffin for morphometric assessment, or
inflated with diluted Tissue-Tek OCT (Sakura Finetek
U.S.A., Torrance, CA, USA) (50% vol/vol in RNase-free
PBS containing 10% sucrose), and then stored frozen at
-80°C for RNA and protein extraction as previously
described [21,22].
Morphometric assessment
Four mid-sagittal sections of the lungs (4 μm) were
stained with hematoxylin and eosin. An observer with
Table 1 Clinical Characteristic of Control and Pulmonary
Fibrosis Patients
control Pulmonary
Fibrosis
Number of subjects, female/male 10, 7/3 12, 8/4
Age, yr 66 ± 4 63 ± 2
Cigarette smoking, never/former/current 10/0/0 7/1/4
Pathological diagnosis NA 3 UIP
9 NSIP
VC, % pred 109 ± 5 88 ± 6
FEV1/FVC, % 76 ± 1 80 ± 2
DLCO, % pred 103 ± 7 65 ± 5
PaO2, torr 87 ± 3 77 ± 4
Collagen vascular disease 0 3 Sjs
(Mean ± SE).
UIP, usual interstitial pneumonia (*: p < 0.05 vs. control).
NSIP, nonspecific interstitial pneumonia.
Sjs, Sjögren’s syndrome.
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assessed 30 randomly chosen regions per tissue sample
at a magnification of ×100 and determined the average
score of fibrosis. The severity of fibrosis was semiquanti-
tatively assessed using Ashcroft score, as previously
described [23,24]. Briefly, the grade of lung fibrosis was
scored on a scale of 0 to 8 as follows: grade 0, normal
lung; grade 1, minimal fibrous thickening of alveolar or
bronchial walls; grade 3, moderate thickening of walls
without obvious damage to the lung architecture; grade
5, increased fibrosis with definite damage to the lung
structure and formation to fibrous bands or small
fibrous masses; grade 7, severe distortion of structure
and large fibrous areas; grade 8, total fibrous obliteration
of the field. If there was any difficulty in deciding
between two odd-numbered categories, the field would
be given the intervening even-numbered score. Alveolar
bronchiolization was identified as cells resembling
bronchiolar epithelium lining normal or thickened
alveolar walls, often in an acinar formation, and was
graded from 1 to 3 as previously described [20]. The
composite bronchiolization score was calculated as the
incidence of bronchiolization multiplied by each grade
and summed up in each animal.
Immunohistochemistry
Catalase immunohistochemistry was performed using a
CSA kit (DAKO Japan, Kyoto, Japan) according to the
manufacturer’s protocol. Tissue sections were incu-
bated with a rabbit anti-catalase antibody (Calbio-
chem-Novabiochem, San Diego, CA, USA) diluted
1:10,000 at room temperature for 1 hour. The sections
were counterstained with hematoxylin. To avoid inter-
r u nv a r i a t i o n si ni m m u n o r e a c tions, all specimens were
stained in the same run using identical reagents. Stain-
ing of alveolar macrophages served as the internal
positive control for catalase. Rabbit serum was used
for negative controls.
Laser capture microdissection (LCM) of bronchiolar
epithelial cells in mouse lung
Bronchiolar epithelial cells were selectively obtained
from the lungs by LCM using a PixCell II System (Arc-
turus Engineering, Mountain View, CA, USA). Bronch-
iolar epithelial cells were retrieved from the junction of
the terminal bronchioles and alveolar ducts and proxi-
mally along airways of up to ~250 μm in diameter, as
described [22,25].
Quantitative reverse transcriptase-polymerase chain
reaction (RT-PCR)
Total RNA was extracted using the RNeasy
® Mini kit
(Qiagen, Hilden, Germany) from lung tissue homogenates
or LCM-retrieved bronchiolar epithelial cells. Comple-
mentary DNA templates were synthesized using RT
(Applied Biosystems, Foster City, CA, USA) and mRNA
levels were quantified by a 5’-exonuclease based fluoro-
genic PCR using a 7300 Real Time PCR System (Applied
Biosystems), as described [22,25], with TAKARA master
mix (TAKARA BIO INC, Shiga, Japan) according to
the manufacturer’s instructions. The TaqMan Gene
Expression Assays probes
® were Hs00156308_m1 for
human catalase, Mm00437992_m1 for murine catalase,
Mm01178820_m1 for murine transforming growth
factor-b (TGF-b), Mm00802331_m1 for murine collagen
III, Mm00433659_m1 for CXCL1/KC (keratinocyte-
derived chemokine), Mm 00434228_m1 for murine inter-
leukin-1b (IL-1b), and Mm 00436450_m1 for murine
CXCL2/MIP-2 (macrophage inflammatory protein-2)
(Applied Biosystems), and the levels were normalized
against glyceraldehyde-3-phosphatase-dehydrogenase
(GAPDH) mRNA (human) or b2-microglobulin
(b2 MG) mRNA (mouse). In some experiments,
18S rRNA (Ribosomal RNA control reagents
®)o r
b-glucuronidase (BGUS) (Mm 00446953_m1) were used
for normalization.
Western blotting
Frozen lung tissues were homogenized and the samples
were prepared as previously described [18]. The samples
(10 μgo fp r o t e i n )w e r er e s o l v e db ye l e c t r o p h o r e s i s
under reducing conditions and transferred to Immun-
Blot PVDF membranes (Bio-Rad Laboratories, Hercules,
CA, USA). The membranes were then incubated over-
n i g h ta t4 ° Cw i t hr a b b i ta n t i - catalase antibody (Calbio-
chem-Novabiochem) diluted 1:4,000 followed by
horseradish peroxidase-conjugated anti-rabbit immuno-
globulin (DAKO Japan) diluted 1:20,000. Because the
use of b-actin as a normalizing control is limited in
human lung diseases [26], loading homogeneity was
determined based on an equal amount of total protein
in each sample.
Lung catalase and glutathione peroxidase activity
Frozen lung tissues were homogenized in lysis buffer
and used for assessment of the activities of calatase and
glutathione peroxidase using commercially available kits,
according to the manufacturer’s protocol (Cayman Che-
mical, Ann Arbor, Michigan, USA). Catalase activity was
determined based on the reaction of the enzyme with
methanol in the presence of an optimal concentration of
hydrogen peroxide. The enzyme reaction of glutathione
peroxidase was monitored by adding tert-butyl hydro-
peroxide as a substrate in the presence of glutathione,
glutathione reductase and nicotinamide adenine
dinucleotide phosphatase.
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Collagen content of the lung was determined by assay-
ing soluble collagen using the Sircol Collagen Assay kit
(Biocolor, Belfast, Northern Ireland), according to the
manufacturer’s instructions.
Assessment of protein carbonyls
Carbonylation of BALF proteins was assessed, as
described previously [27,28]. Briefly, 16 μlo fu n c o n c e n -
trated BALF was derivatized with dinitrophenylhydra-
zine (DNP) using the OxyBlot Protein Oxidation
Detection Kit (Chemicon International, Temecula, CA)
and was separated by electrophoresis on 10% SDS-poly-
acrylamide electrophoresis gels. Western blots were per-
formed using anti-DNP antibody, followed by scanning
with a GT-9500 scanner (Epson, Nagano, Japan); the
intensity of the bands was calculated using NIH Image
software (version 1.62). On each blot, the recorded total
DNP intensity of all bands detected in each lane or
bands detected for the same molecular weight was
divided by that of a standard sample. The carbonyl con-
tent is given in terms of Arbitrary Units (AU).”
Statistical analysis
Results are expressed as mean ± SEM. The statistical
significance of the values at each time point after bleo-
mycin treatment was evaluated by Kruskal-Wallis test.
Mann-Whitney U test was applied to comparisons
between two groups in the mouse and human studies.
Differences were considered significant at p < 0.05 (Stat-
View J 5.0, SAS Institute Inc., Cary, NC, USA).
Results
Catalase is decreased in human pulmonary fibrosis
We first assessed whether the catalase activity is altered
in human fibrotic lungs. The levels of catalase activity in
lung tissue were significantly lower in pulmonary fibro-
sis compared with controls (p = 0.0010), without any
obvious difference between UIP and NSIP (318.8 ± 67.6
nmol/min/mg protein vs. 249.0 ± 29.5; NS) (Figure 1A).
To assess whether the reduction in catalase activity in
f i b r o t i cl u n g si sd u et ot h ed e c r e a s e ds y n t h e s i so fc a t a -
lase, we quantified catalase expression in lung tissues
using Western blotting and quantitative RT-PCR. The
level of catalase protein in the fibrotic lungs tended
to be lower than in the control lungs (p = 0.0559)
(Figure 1B). The level of lung tissue catalase mRNA was
significantly lower in the fibrotic lungs than control
lungs (p = 0.0008) (Figure 1C). The significance of cata-
lase mRNA expression between the two groups persisted
when normalized by 18s rRNA (0.62 ± 0.1 vs. 1.6 ± 0.1,
p = 0.0002). These results show that the diminished cat-
alase activity in the fibrotic lungs is associated with cata-
lase downregulation at the protein and mRNA levels,
although it should be noted that this outcome is also
related to a difference in the cellularity of homogenized
lung tissues between control and fibrotic lungs.
Immunohistochemistry was then performed to localize
catalase in fibrotic lungs. Catalase was predominantly
localized in bronchiolar epithelial cells (Figure 2A) as
well as in type II epithelial cells and alveolar macrophages
in control lungs. This was in line with findings by Kaar-
teenaho-Wiik and Kinnula [12]. In contrast, bronchiolar
epithelial cells in fibrotic lungs showed decreased catalase
expression to various degrees (Figure 2B). Abnormal re-
epithelialization, such as bronchiolization (Figure 2C)
and squamous metaplasia (Figure 2D), were barely
stained for catalase. Fibroblastic foci were exclusively
negative for catalase (Figure 2E).
Contamination by red blood cells does not contribute to
catalase activity of the lungs
Because high catalase levels are found in erythrocytes
[29], we removed residual blood by perfusing lungs with
saline and compared catalase activity between perfused
and unperfused lungs. The catalase activity of saline-
perfused lungs was not statistically different from unper-
fused lungs (252.0 ± 21.4 nmol/min/mg protein vs.
189.7 ± 27.7, NS), suggesting that catalase activity in
lung homogenates is not due to circulating erythrocytes,
but rather originates from lung structural cells.
Catalase is decreased in bleomycin-induced lung fibrosis
in C57BL/6J mice
Several studies have demonstrated that bleomycin
administration decreases the antioxidant capacity in
lung tissue, which aggravates pulmonary fibrosis [30,31].
In order to investigate whether catalase activity and
mRNA are also decreased during the development of
lung fibrosis, C57BL/6J mice were subjected to intratra-
cheal administration of bleomycin. The levels of catalase
activity in whole lung homogenates were significantly
lower at 7, 14, and 21 days after intratracheal bleomycin
administration compared with untreated controls (p <
0.01) (Figure 3A), which is in line with the findings of
previous studies [32,33]. Whole lung catalase mRNA
expression was significantly decreased at 7 and 14 days
after intratracheal bleomycin administration compared
with controls (p < 0.01, respectively) (Figure 3B). The
significance of catalase mRNA expression among the
groups persisted at 7 and 14 days when normalized by
BGUS (p < 0.05, respectively). The data suggest that cat-
alase is downregulated at transcriptional levels, resulting
in impaired catalase activity in bleomycin-induced lung
fibrosis in mice, as was seen in human IP lungs. We
observed that catalase is predominantly expressed in
bronchiolar epithelium in normal lungs, and is dimin-
ished in IP lungs, especially in bronchiolar epithelium
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Page 6 of 13and in abnormal re-epithelialization, such as bronchioli-
zation and squamous metaplasia in humans (Figure 2).
We then examined the dynamic change in bronchiolar
catalase expression following administration of bleomy-
cin in mice. Using LCM we harvested bronchiolar
epithelial cells from lungs in order to quantify catalase
mRNA expression in vivo, as previously described [18].
Catalase mRNA was present in bronchiolar epithelial
cells, and the expression levels were significantly lower
at 7 days after bleomycin administration compared with
untreated lungs (p = 0.009) (Figure 3C).
No compensatory increase in glutathione peroxidase
activity was observed for catalase in bleomycin-treated
acatalasemic mice
To investigate the consequence of decreased catalase
activity in the lung during the development of fibrosis,
we used acatalasemic mice (C3H/AnLCsbCsb). The
untreated lungs of acatalasemic mice possess only 8.1%
of catalase activity compared with those of wild-type
mice (C3H/AnLCsaCsa) (Figure 4A), although acatalase-
mic mice demonstrate equivalent levels of catalase
mRNA compared with wild-type mice (0.9 ± 0.1 vs. 0.6
± 0.1, NS). The lung catalase activity in wild-type mice
continued to decrease until 14 days following bleomycin
administration (Figure 4A), which was consistent with
the findings in C57BL/6J mice shown in Figure 3A. The
catalase activity remained markedly lower in acatalase-
mic mice compared to wild-type mice at any time point
following bleomycin administration (p < 0.01, respec-
tively) (Figure 4A). Catalase and glutathione peroxidase
are the two major enzymes physiologically involved in
the detoxification of hydrogen peroxide, and thus pro-
tect tissue from oxidant-mediated injury. Therefore we
next examined whether glutathione peroxidase could
compensate for catalase. Untreated acatalasemic mice
had higher glutathione peroxidase activity in the lungs
compared with wild-type mice, although no further
increase in glutathione peroxidase activity was observed
in the lungs of acatalasemic mice following bleomycin
administration (Figure 4B). On the other hand, glu-
tathione peroxidase activity was significantly increased
at 7 and 14 days in wild-type mice along with a
decrease in lung catalase activity. These data suggest a
difference in the compensatory mechanism of glu-
tathione peroxidase between wild-type and acatalasemic
mice.
Acatalasemia sensitizes bleomycin induced-inflammation
and prolongs bleomycin induced-upregulation of
proinflammatory cytokines
We then used the acatalasemic mice to address how the
deficiency in catalase activity affected the lung inflam-
mation induced by bleomycin. In BAL fluid, total
numbers of inflammatory cells were increased after
bleomycin administration in both types of mice. How-
ever, the elevations of total cell numbers, lymphocytes
and neutrophils were prolonged in acatalasemic mice
compared with wild-type mice and showed significant
difference at 14 days between wild-type mice and
acatalasemic mice (Table 2), suggesting sustained
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Page 7 of 13inflammation in acatalasemic mice after bleomycin
administration.
In bleomycin-induced lung injury animal models,
inflammatory cytokines have been reported to be tempora-
rily increased in the lungs [34]. In order to elucidate the
mechanism of sustained inflammation in acatalasemic
mice following bleomycin administration, we quantified
the levels KC, MIP-2 and IL-1b expression in whole lung
homogenates. KC mRNA was elevated at 7 days after bleo-
mycin administration in both types of mice, but acatalase-
mic mice showed further elevation at 14 days (Figure 5A).
These tendencies were also found for MIP-2 mRNA and
IL-1b mRNA (Figure 5B, C). Sustained upregulation of
these proinflammatory cytokines in acatalasemic mice
may, at least in part, explain the elevation in neutrophils
even at 14 days after bleomycin administration.
Acatalasemia accelerates fibrosis and bronchiolization
and increases expression of TGF-b in the lungs following
bleomycin administration
Finally we examined whether the lowered catalase activ-
ity in the lungs would worsen lung fibrosis induced by
bleomycin. The lungs of untreated acatalasemic mice
appeared morphologically normal, and no fibrosis was
observed at the level of light microscopy, as previously
described [35].
Fibrosis was more severe and more inflammatory cells
were present in the lungs of acatalasemic mice com-
pared with wild-type mice at 14 days after bleomycin
administration (Figure 6A, B). Acatalasemic mice
demonstrated significantly higher Ashcroft scores at
14 days after bleomycin administration, compared with
those of wild-type mice (p = 0.0441) (Figure 6C).
Bronchiolization is a metaplastic lesion characterized by
cells resembling the lining of the bronchiolar epithelium
with normal or thickened alveolar walls, often in acinar
formation. It is derived from terminal bronchiolar
epithelium through aberrant cell proliferation and
migration. It should also be noted that bronchiolization
appeared in fibrotic lesions both in wild-type and acata-
lasemic mice, although the composite bronchiolization
score was significantly higher in acatalasemic mice com-
pared to wild-type mice in accordance with the severity
of fibrosis (p = 0.0387) (Figure 6A, B, Table 3). Lung
fibrosis is characterized by the accumulation of extracel-
lular matrix proteins, such as collagen III. A variety of
pro-fibrotic molecules are believed to play roles in the
regulation of the fibrogenic process, in which TGF-b is
particularly considered to promote fibrosis [4,36]. In our
acatalasemic mice, the levels of TGF-b expression were
significantly higher in whole lungs at 7 days after bleo-
mycin treatment compared to those of wild-type mice
(p = 0.0065) (Figure 7A). Collagen III expression was
higher in acatalasemic mice at 7 days and total lung
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activities in wild-type and acatalasemic mice. (A) Lung catalase
activity is decreased after bleomycin administration in wild-type
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Table 2 Bronchoalveolar Lavage Fluids in Wild-type and
Acatalasemic Mice
Total cells
(× 10
4/ml)
Cell differentials (× 10
4/ml)
Macrophages
Lymphocytes Neutrophils
Wild-type (C3H)
Day 0 (n = 6) 1.4 ± 0.5 1.3 ± 0.5 0.1 ± 0 0 ± 0
Day 7 (n = 7) 17.8 ± 7.0* 10.7 ± 4.8 2.6 ± 1.3 4.3 ± 2.0*
Day 14 (n = 12) 8.7 ± 1.1* 5.9 ± 0.7 1.7 ± 0.3 1.1 ± 0.4*
Acatalasemic
Day 0 (n = 7) 1.5 ± 0.4 1.3 ± 0.3 0.2 ± 0.1 0 ± 0
Day 7 (n = 7) 6.5 ± 0.9* 4.6 ± 0.6* 1.1 ± 0.2* 0.8 ± 0.2*
Day 14 (n = 10) 13.5 ± 1.5*
† 7.6 ± 1.1* 3.2 ± 0.4*
† 2.8 ± 0.7*
†
*: p < 0.05 vs. Day 0 (Mean ± SE).
†: p < 0.05 vs. Wild-type mice (C3H/AnLCsaCsa).
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Page 8 of 13collagen was also significantly elevated at 14 days after
bleomycin administration compared to wild-type mice
(p = 0.0455 and p = 0.003, respectively), suggesting
accelerated fibrinogenesis in the acatalasemic mice
(Figure 7B and 7C). To assess whether acatalasemic
mice exhibit excessive oxidative stress in the lungs after
bleomycin administration, we examined BALF protein
carbonyls, an oxidative stress marker, at 0, 7 and 14
days. Bleomycin induced the increase of total carbony-
lated protein and 68 kDa carbonylated protein both in
wild-type and acatalasemic mice. Acatalasemic mice
showed modest further increases at 0 and 7 days, but
the differences did not reach the statistical significance
between wild-type and acatalasemic mice (Figure 8A
and 8B).
Discussion
In human fibrotic lungs, we observed a decrease in cata-
lase activity as well as in mRNA and protein levels.
Bronchiolar epithelium is a major site of catalase expres-
sion in normal adult lungs. Decrease of catalase in
bronchiolar epithelium and in abnormal re-epithelializa-
tion suggests the presence of intracellular oxidative
stress in those specific cell types in fibrotic lungs. We
have been long interested in the role of aberrant prolif-
eration of bronchiolar epithelial cells, such as alveolar
bronchiolization and squamous metaplasia, in the patho-
physiology of lung fibrosis. Although it appears
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fibrosis along with infiltration of inflammatory cells in the lungs (B).
In fibrotic regions of the lungs, clusters of cuboidal bronchiolar-
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Page 9 of 13temporarily in the bleomycin model, the degrees of
alveolar bronchiolization and of fibrosis were higher in
acatalasemic mice compared to those in wild-type mice.
We previously demonstrated that those cells of abnor-
mal re-epithelialization were characterized by
diminishment of caveolin-1 and the increased expression
of matrix metalloproteinases (MMPs) and extracellular
matrix metalloproteinase inducer (EMMPRIN) in lung
fibrosis [17,18]. Furthermore, we found that MMP-9 is
required for the formation of bronchiolization [20]. A
recent report has indicated that MMP-7 (matrilysin-1)
mediates the aberrant cell proliferation and migration of
bronchiolar epithelial cells, implying potential prema-
lignancy [37]. The interaction of these molecules with
catalase has been reported in other cell types. For exam-
ple, treatment with a catalase/superoxide dismutase
mimetic, or adenoviral-mediated overexpression of cata-
lase, inhibits hydrogen peroxide-stimulated EMMPRIN
upregulation in cardiac myocytes [38]. In another study
detoxification of hydrogen peroxide by administration of
catalase resulted in a decrease in the MMP activity and
cell proliferation in metastatic tumor cells [39]. Collec-
tively, these findings suggest that the loss of catalase in
bronchiolar epithelium is involved in abnormal repair of
epithelium in fibrosis directly or indirectly via MMP
molecules. It also should be noted that fibroblastic foci
Table 3 Incidence of bronchiolization in the lung
Grade 1 Grade 2 Grade 3 composite
bronchiolization
score
Wild-type (C3H)
(n = 8)
2.9 ± 1.0 2.0 ± 0.8 3.0 ± 1.3 13.4 ± 4.0
Acatalasemic
(n = 6)
6.7 ± 2.0 2.0 ± 0.7 3.0 ± 1.1 28.3 ± 5.0*
*: p < 0.05 vs. Wild-type mice (C3H/AnLCsaCsa) (Mean ± SE).
Grade 1: Single alveolus lined by cuboidal epithelial cells or a single isolated
acinar structure consisting of cuboidal epithelial cells adjacent to a terminal
bronchiole.
Grade 2: 2 to 4 clustered tubular structures consisting of single-layered
cuboidal epithelial cells adjacent to a terminal bronchiole.
Grade 3: More than 4 clustered tubular structures single-layered or stratified
cuboidal epithelial cells.
Wild-type (C3H)
Acatalasemic
15
2
m
R
N
A
*
p=0.0065
p=0 057
A
5
1
1.5
m
R
N
A
/
ȕ
2
M
G
 
*
*
p=0.057
2
R
N
A
B
0
.5
T
G
F
-
ȕ
Day 0 Day 7 Day 14
1
1.5
2
R
N
A
/
ȕ
2
M
G
 
m
R
*
* p=0.0455
B
0
.5
C
o
l
l
a
g
e
n
 
I
I
I
 
m
R
D0 D D1 4
*
Day 0 Day 7 Day 14
1400
1600
n
g
) C *
p=0.003
600
800
1000
1200
1400
l
a
g
e
n
 
(
u
g
/
 
g
 
l
u
n
0
200
400
Day 0D a y 7D a y 14
T
o
t
a
l
 
c
o
l
Figure 7 Changes in expression of TGF-b and collagen in wild-
type and acatalasemic mice. TGF-b mRNA (A), collagen III mRNA
(B) and total collagen content (C) of the lungs are higher in
acatalasemic mice at 7 and 14 days, at 7 days, and 14 days,
respectively. b2MG, b2-microglobulin. *; p < 0.05 vs. Day 0. Day 0;
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Although the origin of fibroblast and fibroblastic foci
remains to be clarified, they are not source of catalase
in fibrotic lungs.
We next addressed whether lowered catalase activity
would subsequently worsen inflammation/fibrosis in the
lungs. The acatalasemic mouse strain was established by
Feinstein et al. from the progeny of x-ray-irradiated
mice [40]. We found in the present study that the lung
tissues of acatalasemic mice possess only 8.1% of the
catalase activity of wild-type mice, although acatalasemic
mice demonstrate equivalent levels of catalase mRNA.
This suggests that the mutation does not act at the level
of gene transcription or mRNA stability, but rather at
the level of mRNA translation and/or protein turnover,
as reported for other organs of acatalasemic mice [41].
Taken together with previous reports that acatalasemic
mice are susceptible to oxidative renal fibrosis [35,42]
and peritoneal fibrosis [43], our data also support that
catalase plays a crucial role in protection from fibrotic
disorders.
There were a few unexpected findings in this study,
namely the prolonged upregulation of proinflammatory
cytokines, including neutrophilic chemokines, KC and
MIP-2, and subsequent neutrophilic inflammation fol-
lowing bleomycin administration in acatalasemic mice.
Our data suggest that a lack of catalase activity poten-
tially enhances the recruitment of neutrophils after bleo-
mycin administration into the lungs. Sustained
upregulation of proinflammatory cytokines may, at least
partly, explain the elevation in neutrophils even at
14 days after bleomycin administration. Although the
cellular source of these proinflammatory cytokines
remains to be determined in this model, the upregula-
tion observed may be related to the absence of intracel-
lular catalase activity.
Several limitation of this study should be noted. In the
present study, we used bleomycin for the lung fibrosis
model. Bleomycin, a clinically important causative agent
in lung fibrosis, is widely used in experimental models
of human disease resembling pulmonary fibrosis [44].
Although the precise mechanism of bleomycin-induced
fibrosis is yet to be determined, alveolar cell damage
and subsequent pulmonary inflammation is particularly
important in the development of lung fibrosis. Studies
of this model have helped uncover the complexity of
mechanisms involved in the human disease upon under-
standing the limitation. First of all, fibrosis eventually
resolves in mice 6 to 10 weeks after bleomycin injury
[45]. This does not occur in humans. Similar to fibrosis,
the decrease in catalase at the levels of activity and
mRNA expression was also temporal; catalase levels
appeared to increase again at 21 days (Figure 3) and
tended to become restored at 35 days before the
resolution phase (data not shown). This fact is notably
in sharp contrast to the persistent decrease of lung cata-
lase in human IPs (Figure 1). It is also been known that
the susceptibility to fibrosis varies among the different
strains of mice [46-48]. Compared to C57BL/6J mice,
the background strain of acatalasemic mice C3 H is
reportedly to be rather resistant to this model [47]. That
C3 H wild-type mice did not exhibit apparent lung
fibrosis after bleomycin administration is consistent with
the findings shown in Figures 6A and 7. The elevation
of BALF protein carbonyls after bleomycin administra-
tion suggests the presence of extracellular oxidative
stress in the lungs, which is consistent to the previous
papers [49,50]. However, there is no further oxidative
stress in acatalasemic mice as compared to wild type
mice. This raises a possibility that the increased fibrosis
in acatalasemic mice may not be due to excessive extra-
cellular oxidative stress, although this could be related
to an insensitive way of measuring the oxidative stress.
Our result that catalase is decreased in bleomycin-
induced lung fibrosis might be due to changing cellular
dynamics during progression, however, the finding that
the acatalasemic mice get more fibrosis supports the
functional role of catalase in preventing fibrosis.
Taken together, this study supports the concept that a
complicated network consisting of oxidant-antioxidant
imbalance and inflammation closely contributes to the
progression of fibrosis, in which catalase plays a putative
role for protection of the lung.
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